• 1
    Mattson RH. Cramer JA, Collins JF, et al. Comparison of carba-mazepine. phenobarbital. phenytoin and primidone in partial and secondarily generalized tonic-clonie seizures. N Engl. 1 Med 1985; 313:14551.
  • 2
    Mattson RH. Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for complex partial seizures and secondarily generalized tonic clonic seizures in adults. N Engl J Med 1992: 327:76571.
  • 3
    Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. Br Med.J 1996; 313:116974.
  • 4
    Marson AG. Kadir ZA. Hutton JL. Chadwick DW. The new anti-epileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997: 38:85980.
  • 5
    Yusuf S.. Meta-analysis of randomized trials: looking back and looking ahead. Controlled Clin Trials 1997: 18:594601.
  • 6
    Cramer JA, Mattson RH. Scheyer RD, French J.. Meta-analysis of antiepileptic drug trials. Epilepsia 1998; 39:2334.
  • 7
    LeLorier J., Gregoire G., Bcnhaddad A., Lapierre .J, Derderian F.. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997: 337:53642.
  • 8
    Bailar JC. The promise and problems of meta-analysis. N Engl. J Med 337:55960.
  • 9
    Chadwick DW. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia 1997; 38(suppl l):S5962.
  • 10
    Brodie MJ, Dichtcr MA. Antiepileptic drugs. N Engl J Med 1996; 334:16875.
  • 11
    Shorvon S., Stefan H. Overview of the safety of newer antiepileptic drugs. Epilepsia 1997:(suppl l):S4551.
  • 12
    Spilker B. Guide to clinical trials. New York : Raven Press. 1991:480.
  • 13
    Cramer JA. Smith DB. Mattson RH. Delgado-Escueta AV. Collins JF et al. , and the VA Epilepsy Cooperative Study Group. A method of quantification for the evaluation of antiepileptic drug therapy. Neurology 1983; 33(suppl l):2637.
  • 14
    Collins JF, Cramer JA, Mattson RH. and VA Epilepsy Cooperative Study Groups 118 and 264. Comparison of systemic and neurologic effects of standard antiepileptic drugs. Epilepsia 1997: 38(suppl 8):889.
  • 15
    Faught E., French J., Harden C. Glun B., Khan A.. and the Postmarketing Antiepileptic Drug Survey Group (PADS). Adverse effects of topiramate: results from a large postmarketing survey. Epilepsia 1997; 38(suppl 8):978.
  • 16
    French JA. Williams S., Morris G., Tatum W., Privitera M., Postmarketing Antiepileptic Drug Survey Group PADS). Post-markeiing use of topiramate. Epilepsia 1997; 38(suppl 8):96.
  • 17
    Gillam F., Kuzniecky R., Faught E. Black L. Carpenter G. Schrodt R.. Patient-validated content of epilepsy-specific quality of life measurement. Epilepsia 1997; 38:2337.
  • 18
    UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990; 335:11147.
  • 19
    Anhut H. Ashman P. Fuerstein TJ, Sauermann W. Saunders M., Schmidt B.. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study; the International Gabapentin Study Group. Epilepsia 1994: 35:795801.
  • 20
    Sivenius J., Kalvainen R., Ylinen A. Riekkinen P.. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991; 32:53942.
  • 21
    The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled. parallel-group study. Neurology 1993: 43:22928.
  • 22
    Matsuo F., Bergen D. Faught E. et al. Placebo-controlled study of the efficacy and safety of lamotriginc in patients with partial seizures: US Lamotriginc Protocol No. 5 Clinical Trial Group. Neurology 1993: 43:228491.
  • 23
    Binnie D. Debets RM. Engelsman M. et al. Double-blind crossover trial of lamotrigine (Lamictal) as add on therapy in intractable epilepsy. Epilepsy Res 1989: 4:2229.
  • 24
    Jawad S., Richens A. Goodwin G. Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989: 30:35663.
  • 25
    Loiseau P. Yuen AW. Duche B., Menager T. Arne Bes MC. A randomized double-blind placebo-controlled cross-over add on trial of lamotrigine in patients with treatment resistant partial seizures. Epilepsy Res 1990: 7:13645.
  • 26
    Messcnheimer J. Ramsay RE. Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994: 35:11321.
  • 27
    Schapel GJ. Beran RG. Vajda FJ. et al. Double-blind, placebo-controlled, cross-over study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993: 56:44853.
  • 28
    Smith D. Baker G. Davies G., Dewey M. Chadwick DW. Outcomes of add on treatment with lamotrigine in partial epilepsy. Epilepsy 1993: 34:31222.
  • 29
    Ben-Menachem E.. International experience with tiagabine add-on therapy. Epilepsia 1995; 6(suppl 6):S 1421. [101, 103, 106, 107, 109 studies|.
  • 30
    Sachdco RC. Leroy RF. Krauss GL. et al. . for the Tiagabine Study Group. Tiagabine therapy for complex partial seizures: a dose frequency study. Arch Neurol 1997: 54:595601.
  • 31
    Richens A. Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995: 21:3742.
  • 32
    Uthman BM, Rowan AJ, Ahmann PA. et al. Tiagabine for complex partial seizures: a randomized, add-on. dose-response trial. Arch Neurol 1998: 55:5662.
  • 33
    Faught E., Wider B.I. Ramsay RE, et al. Topiramate controlled dose ranging trial refractory partial epilepsy using 200, 400. and 600 mg daily dosages. Neurology 1996: 46:168490.
  • 34
    Sharief M., Viteri C., Ben-Menachem E. et al. Double-blind, placebo-controlled. dose ranging study of topiramate in patients with partial epilepsy. Epilepsy Res 1996: 25:21724.
  • 35
    Ben-Menachem E.. Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: the European experience. Epilepsia 1997: 38(suppl l):S2830. JY1. Y2. Y3 studies!.
  • 36
    Tassinari CA, Michelucci R. Chauvel P., et al. Double-blind placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996: 37:7638.
  • 37
    Privitera M., Fincham R. Renty J., et al. Topiramate controlled dose ranging trial in refractory partial epilepsy using 600, 800, and 1000 mg daily dosages. Neurology 1996: 46:167883.
  • 38
    Ben-Menachem E. Henriksen O. Dam M. Schmidt D.. Double-blind placebo-controlled trial of topiramate as add-on treatment in patients with refractory partial epilepsy. Epilepsia 1996: 36:53943.
  • 39
    Penry JK. Wilder BJ. Rajesh C., et al. Multicenter dose-response study of vigabatrin in adults with focal (partial) epilepsy [Abstract]. Epilepsia 1993; 34(suppl 6):67.
  • 40
    Beran RG. Berkovic SF. Buchanan N. et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure 1996: 5:25965.
  • 41
    French JA. Mosier M. Walker S., Somerville K., Sussman N., and the Vigabatrin Protocol 024 Investigative Cohort. A double-blind. placebo-controlled study of vigabatrin 3 g/day in patients with uncontrolled partial seizures. Neurology 1996: 46:5461.
  • 42
    Grunewald RA. Thompson PJ. Corcoran R. Corden Z. Jackson GD, Duncan JS. Effects of vigabatrin on partial seizures and cognitive function. .J Neurol Neurosurg Psychiatry 1994: 57:105763.
  • 43
    Begg C. Cho M. Eastwood S. et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996: 276:6379.